Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 5 Combined analysis of G1m status according to change in DAS28 and to the EULAR criteria

From: Rheumatoid arthritis response to treatment across IgG1 allotype – anti-TNF incompatibility: a case-only study

Strata G1m genotype a number Baseline DAS28 ΔDAS28 Beta b P-value b R c NR c OR b P-value b
All patients G1m1,17+ 523 6.3 ± 1.1 2.3 ± 1.4 0.09 0.002 153 (29.3) 79 (15.1) 1.5 0.035
  G1m1,17- 429 6.2 ± 1.2 2.0 ± 1.5    98 (22.8) 90 (21.0)   
INX G1m1,17+ 387 6.3 ± 1.1 2.3 ± 1.5 0.11 0.001 116 (30.0) 67 (17.3) 1.5 0.03
  G1m1,17- 314 6.2 ± 1.3 1.9 ± 1.5    67 (21.3) 78 (24.8)   
ADM G1m1,17+ 136 6.2 ± 1.1 2.5 ± 1.4 0.03 0.55 37 (27.2) 12 (8.8) 1.1 0.57
  G1m1,17- 115 6.2 ± 1.2 2.5 ± 1.4    31 (27.0) 12 (10.4)   
  1. aCarrier status; banalyses adjusted for baseline DAS28 and gender (and anti-TNF for All patients); cnumber (% response class/all patients with this genotype). ADM, adalimumab; DAS28, disease activity score in 28 joints; IFX, infliximab; NR, non-responders; R, responders.